Results

Total Results: 4,732 records

Showing results for "secondary".

2521. 2015-04 (pdf file)
      hcup-us.ahrq.gov/reports/methods/2015-04.pdf
      January 01, 2015 - the first-listed (primary) payer, whereas the MedPAR count includes discharges with Medicare as a secondary … diagnosis w mcc 3,486 3,345 -4.0 847 Chemotherapy w/o acute leukemia as secondary diagnosis w cc 26,431 … 24,565 -7.1 848 Chemotherapy w/o acute leukemia as secondary diagnosis w/o cc/mcc 1,302 1,345 … system & connective tissue w mcc 3,364 3,355 -0.3 429 846 Chemotherapy w/o acute leukemia as secondary … Use of Secondary Procedure Days in the AHRQ Quality Indicators, Version 3.1 Table 5.

2522. Procedure Manual Section 2. Topic Selection, Prioritization, and Updating | United States Preventive Services Taskforce
      www.uspreventiveservicestaskforce.org/uspstf/about-uspstf/methods-and-processes/procedure-manual/procedure-manual-section-2-topic-selection-prioritization-and-updating
      June 22, 2025 - service should meet the definition of primary prevention (i.e., avoid the development of disease) or secondary

2523. Maskedstats Nrd 2022 Core Weighted (pdf file)
      hcup-us.ahrq.gov/db/nation/nrd/stats/MaskedStats_NRD_2022_Core_Weighted.PDF
      January 01, 2022 - OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH MCC 8,817 0.03% 837: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … SEC DX WITH CC OR HIGH DOSE CHEMOTHERAPY AGENT 9,074 0.03% 838: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … CHEMO W/ ACUTE LEUKEMIA AS SEC DX WITHOUT CC/MCC 5,981 0.02% 839: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS WITH MCC 17,248 0.05% 847: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH … CC 68,195 0.21% 848: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITHOUT CC/MCC 1,972

2524. Methods Applying AHRQ Quality Indicators to Healthcare Cost and Utilization Project (HCUP) Data for the Tenth (2012) NHQR and NHDR (pdf file)
      hcup-us.ahrq.gov/reports/methods/2012-02.pdf
      January 01, 2012 - Use of Secondary Procedure Days in AHRQ Quality Indicators, Version 4.1 ...........20 Table 5. … Use of Secondary Procedure Days in AHRQ Quality Indicators, Version 4.1 Eight PSIs and four PDIs … disease PQI 7 Hypertension PQI 8 Congestive heart failure PQI 8B* Congestive heart failure secondary … Use of Secondary Procedure Days in the AHRQ Quality Indicators, Version 3.1 Table 5. … Use of Secondary Procedure Days in AHRQ Quality Indicators, Version 4.1 Table 5.

2525. Kid 2022 Maskedstats Core (pdf file)
      hcup-us.ahrq.gov/db/nation/kid/tools/stats/KID_2022_MaskedStats_Core.PDF
      January 01, 2022 - OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH MCC 1,975 0.07% 837: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … SEC DX WITH CC OR HIGH DOSE CHEMOTHERAPY AGENT 3,051 0.10% 838: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … CHEMO W/ ACUTE LEUKEMIA AS SEC DX WITHOUT CC/MCC 1,827 0.06% 839: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS WITH MCC 3,515 0.12% 847: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH … CC 17,658 0.59% 848: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITHOUT CC/MCC 513

2526. Kid 2022 Maskedstats Core Weighted (pdf file)
      hcup-us.ahrq.gov/db/nation/kid/tools/stats/KID_2022_MaskedStats_Core_Weighted.PDF
      January 01, 2022 - OR WITH HIGH DOSE CHEMOTHERAPY AGENT WITH MCC 2,696 0.05% 837: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … SEC DX WITH CC OR HIGH DOSE CHEMOTHERAPY AGENT 4,170 0.07% 838: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … CHEMO W/ ACUTE LEUKEMIA AS SEC DX WITHOUT CC/MCC 2,485 0.04% 839: CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS WITH MCC 4,801 0.08% 847: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH … CC 24,072 0.43% 848: CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITHOUT CC/MCC 702

2527. Nis 2005 Summarystats Core Weighted (pdf file)
      hcup-us.ahrq.gov/db/nation/nis/tools/stats/NIS_2005_SummaryStats_CORE_Weighted.PDF
      January 01, 2005 - NEOPL W OTHER O.R.PROC 5396 0.01 409: RADIOTHERAPY 5003 0.01 410: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … W CC 60245 0.15 464: SIGNS & SYMPTOMS W/O CC 19693 0.05 465: AFTERCARE W HISTORY OF MALIGNANCY AS SECONDARY … DIAGNOSIS 2972 0.01 466: AFTERCARE W/O HISTORY OF MALIGNANCY AS SECONDARY DIAGNOSIS 26289 0.07 467 … & LIMB REATTACHMENT PROCEDURES OF UPPER EXTREMITY 36504 0.09 492: CHEMOTHERAPY W ACUTE LEUKEMIA AS SECONDARY … Percent of Total 98: Essential hypertension 73654 0.19 99: Hypertension with complications and secondary

2528. Enhancing Complex Care through an Integrated Care Coordination Information System - Final Report (pdf file)
      digital.ahrq.gov/sites/default/files/docs/publication/r18hs017832-dorr-final-report-2012.pdf
      January 01, 2012 - Organize the needs into a hierarchy of primary, secondary, and (if necessary) tertiary needs; 4. … patients in care coordination clinics; and 3) quality of care would be higher in quality clinics 4) Secondary … Secondary outcomes were preventable hospitalizations (using the PQI methodology), preventable … descriptive statistics by allocation cluster and risk group for rates of hospitalizations, ED visits, and secondary

2529. Urinary-Incontinence-Treatment Research-Protocol (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/urinary-incontinence-treatment_research-protocol.pdf
      September 30, 2010 - condition-specific measure of quality of life developed to address issues related specifically to UI Secondary … incontinence (total, mixed, stress, urgency), quality of life in women with UI, harms after treatment, or secondary … Secondary data analysis, nonsystematic reviews, letters, or comments; 5. … Secondary-care treatment patterns in the UK for women with urinary incontinence.

2530. Chronic-Kidney-Disease-Anemia-2011 Executive (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/chronic-kidney-disease-anemia-2011_executive.pdf
      January 01, 2011 - sex, comorbid conditions, erythropoiesis-stimulating agent resistance, protein energy malnutrition secondary … that a given study that reported its primary outcome well but conducted an incomplete analysis of a secondary … conditions, erythropoiesis-stimulating agent resistance, protein energy malnutrition secondary … associated with testing and associated treatments (e.g., test-related anxiety, adverse events secondary

2531. VitaminD, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Evidence Report and Systematic Review for the USPSTF (pdf file)
      www.uspreventiveservicestaskforce.org/home/getfilebytoken/Yc24U4wMLXGoqE5NjwRVA6
      April 17, 2018 - the Cochrane review included participants with osteoporosis, institu- tionalized participants, and secondary … self-report to identify cases and others relying on adverse event reporting dur- ing study monitoring or on secondary … Effect of monthly high-dose vitamin D supplementation on falls and non-vertebral fractures: secondary … Risk of heart failure among postmenopausal women: a secondary analysis of the randomized trial of vitamin

2532. AHRQ EvidenceNOW: Building State Capacity: Interim Evaluation Report I (pdf file)
      www.ahrq.gov/sites/default/files/wysiwyg/evidencenow/building-capacity/en-bsc-interim-report-1.pdf
      January 31, 2024 - Checking Sessions ......................................................................... 3 2.2.3 Secondary … In addition to primary data, we examined secondary data, including grantee applications, grantee progress … For the evaluation, Abt used a mixed-methods design that used both primary and secondary data, including … (Sections below) Research Questions (Questions in bold are addressed in report) Primary Data Secondary … Data Sources 2.2.1 Key Informant Interviews 2.2.2 Member Checking Sessions 2.2.3 Secondary Data

2533. Introduction To The HCUP Nationwide Readmission Database (NRD) 2021 (pdf file)
      hcup-us.ahrq.gov/db/nation/nrd/NRDIntroduction2021.pdf
      March 01, 2024 - • Payer is assigned using the primary and secondary expected payer (HCUP data elements PAY1 and … If the primary or secondary expected payer indicates Medicare, then the payer category is assigned to … If not Medicare and the primary or secondary expected payer indicates Medicaid, then the payer category … If not Medicare or Medicaid and the primary or secondary expected payer indicates private insurance, … The expected secondary payer data element PAY2 is not available on the NRD.

2534. AHRQ Comparative Health System Performance Initiative: Program Overview and Accomplishments, 2015-2020 (pdf file)
      www.ahrq.gov/sites/default/files/wysiwyg/chsp/CHSP-accomplishments-report-2021.pdf
      January 01, 2021 - . • Constructed a multiyear integrated library of primary and secondary data on physician organizations … The HSPD draws on more than 20 administrative and secondary data sources to identify hospitals and physicians … Using secondary data sources, they identified whether POs were affiliated with a health system and, … The 2016 and 2018 Compendium used several administrative and secondary data resources to identify health … National Survey of Healthcare Organizations and Systems, RAND case studies, and other primary and secondary

2535. Evidence Summary: Osteoporosis to Prevent Fractures: Screening | United States Preventive Services Taskforce
      www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/osteoporosis-screening
      January 14, 2025 - denosumab compared with placebo or no treatment were eligible if most enrolled participants did not have secondary … reports, and the primary outcomes were any fractures (SCOOP, SOS) and MOF (ROSE); hip fractures were secondary … in persons with a history of fragility fracture or medical conditions or medications associated with secondary … Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis … Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.

2536. A Bayesian Missing Data Framework for Multiple Continuous Outcome Mixed Treatment Comparisons (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/indirect-comparisons_research-2013.pdf
      January 01, 2013 - after 1979 that examined physical therapy interventions for community-dwelling adults with knee pain secondary … after 1979 that examined physical therapy interventions for community dwelling adults with knee pain secondary … The target population was adults with knee pain secondary to knee osteoarthritis in outpatient settings … For the present analysis, we selected the pain and disability outcomes as primary and secondary outcomes … Physical Therapy for Knee Pain Secondary to Osteoarthritis. Comparative Effectiveness Review.

2537. Atrial-Fibrillation-Ablation Surveillance (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/atrial-fibrillation-ablation_surveillance.pdf
      May 16, 2013 - AF recurrence (FU=59 mo) HR=2.19, 95% CI: 1.08, 4.46 (female gender as predictor of secondary AF … duration Outcomes and findings HR=2.13, 95% CI: 1.11, 4.10 (hypertension as predictor of secondary … stenosis n=1, arteriovenous femoral fistulae n=1, femoral false aneurysm n=1, anaphylactic shock secondary … to propofol n=1, and ventricular fibrillation secondary to direct current cardioversion n=1) No …     2 pts (pain and fever associated with pericardial and pleural effusions n=1; heart failure secondary

2538. Nis 2002 Summarystats (pdf file)
      hcup-us.ahrq.gov/db/nation/nis/tools/stats/NIS_2002_SummaryStats.PDF
      January 01, 2002 - 29.00 1.42 1.77 PAY1 : Primary expected payer (uniform) 7843762 10220 1.00 6.00 2.24 1.18 PAY2 : Secondary … Distribution for DRG18 DRG18 Frequency Percent of Total 410: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … W CC 10421 0.13 464: SIGNS & SYMPTOMS W/O CC 3652 0.05 465: AFTERCARE W HISTORY OF MALIGNANCY AS SECONDARY … DIAGNOSIS 513 0.01 466: AFTERCARE W/O HISTORY OF MALIGNANCY AS SECONDARY DIAGNOSIS 5435 0.07 467: … & LIMB REATTACHMENT PROCEDURES OF UPPER EXTREMITY 5585 0.07 492: CHEMOTHERAPY W ACUTE LEUKEMIA AS SECONDARY

2539. Nis 2002 Summarystats 10Pct Sample A (pdf file)
      hcup-us.ahrq.gov/db/nation/nis/tools/stats/NIS_2002_SummaryStats_10PCT_SAMPLE_A.PDF
      January 01, 2002 - 0.00 25.00 1.42 1.76 PAY1 : Primary expected payer (uniform) 784365 1033 1.00 6.00 2.24 1.18 PAY2 : Secondary … NEOPL W OTHER O.R.PROC 123 0.02 409: RADIOTHERAPY 160 0.02 410: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS 51 0.01 466: AFTERCARE W/O HISTORY OF MALIGNANCY AS SECONDARY DIAGNOSIS 547 0.07 467: OTHER … JOINT & LIMB REATTACHMENT PROCEDURES OF UPPER EXTREMITY 515 0.07 492: CHEMOTHERAPY W ACUTE LEUKEMIA AS SECONDARY … Leukemias 892 0.11 40: Multiple myeloma 344 0.04 41: Cancer, other Unspecified primary 204 0.03 42: Secondary

2540. Nis 2001 Summarystats 10Pct Sample B (pdf file)
      hcup-us.ahrq.gov/db/nation/nis/tools/stats/NIS_2001_SummaryStats_10PCT_SAMPLE_B.PDF
      January 01, 2001 - 0.00 29.00 1.41 1.77 PAY1 : Primary expected payer (uniform) 743278 1995 1.00 6.00 2.23 1.17 PAY2 : Secondary … Thursday, June 9, 2005 DRG18 Frequency Percent of Total 410: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS 70 0.01 466: AFTERCARE W/O HISTORY OF MALIGNANCY AS SECONDARY DIAGNOSIS 510 0.07 467: OTHER … JOINT & LIMB REATTACHMENT PROCEDURES OF UPPER EXTREMITY 425 0.06 492: CHEMOTHERAPY W ACUTE LEUKEMIA AS SECONDARY … Leukemias 783 0.11 40: Multiple myeloma 345 0.05 41: Cancer, other Unspecified primary 153 0.02 42: Secondary